| Product Code: ETC6187713 | Publication Date: Sep 2024 | Updated Date: Feb 2026 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Australia`s import trend for patient-derived xenograft (PDX) models in 2024 experienced a decline, with a growth rate of -19.2% compared to the previous year. The compound annual growth rate (CAGR) for the period 2020-2024 stood at -27.76%. This negative momentum can be attributed to shifting demand dynamics or evolving market conditions impacting the import landscape.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Patient Derived Xenograft (PDX) Models Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, 2022 & 2032F |
3.3 Australia Patient Derived Xenograft (PDX) Models Market - Industry Life Cycle |
3.4 Australia Patient Derived Xenograft (PDX) Models Market - Porter's Five Forces |
3.5 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Type, 2022 & 2032F |
3.6 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Tumor Type, 2022 & 2032F |
3.7 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Application, 2022 & 2032F |
3.8 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Technique, 2022 & 2032F |
3.9 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By End User, 2022 & 2032F |
4 Australia Patient Derived Xenograft (PDX) Models Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for personalized medicine in Australia |
4.2.2 Rising prevalence of cancer and other diseases driving the need for better preclinical models |
4.2.3 Growing focus on precision medicine and targeted therapies in the healthcare sector |
4.3 Market Restraints |
4.3.1 High cost associated with patient-derived xenograft (PDX) models |
4.3.2 Ethical concerns related to the use of animals in research |
4.3.3 Regulatory challenges and complexities in using PDX models for drug development |
5 Australia Patient Derived Xenograft (PDX) Models Market Trends |
6 Australia Patient Derived Xenograft (PDX) Models Market, By Types |
6.1 Australia Patient Derived Xenograft (PDX) Models Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Type, 2022-2032F |
6.1.3 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Mice Models, 2022-2032F |
6.1.4 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Rat Models, 2022-2032F |
6.2 Australia Patient Derived Xenograft (PDX) Models Market, By Tumor Type |
6.2.1 Overview and Analysis |
6.2.2 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Gastrointestinal Tumor Models, 2022-2032F |
6.2.3 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Lung Tumor Models, 2022-2032F |
6.2.4 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Haematological Tumor Models, 2022-2032F |
6.3 Australia Patient Derived Xenograft (PDX) Models Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Preclinical Drug Development, 2022-2032F |
6.3.3 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Precision Medicine, 2022-2032F |
6.3.4 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Co-Clinical Trials, 2022-2032F |
6.3.5 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Basic Cancer Research, 2022-2032F |
6.3.6 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Biomarker Analysis, 2022-2032F |
6.3.7 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Oncology Research, 2022-2032F |
6.4 Australia Patient Derived Xenograft (PDX) Models Market, By Technique |
6.4.1 Overview and Analysis |
6.4.2 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Heterotopic Implantation, 2022-2032F |
6.4.3 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Orthotropic Implantation, 2022-2032F |
6.5 Australia Patient Derived Xenograft (PDX) Models Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Academic and Research Organizations, 2022-2032F |
6.5.3 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Contract Research Organizations, 2022-2032F |
6.5.4 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Pharmaceutical and Biotechnological Companies, 2022-2032F |
6.5.5 Australia Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Others, 2022-2032F |
7 Australia Patient Derived Xenograft (PDX) Models Market Import-Export Trade Statistics |
7.1 Australia Patient Derived Xenograft (PDX) Models Market Export to Major Countries |
7.2 Australia Patient Derived Xenograft (PDX) Models Market Imports from Major Countries |
8 Australia Patient Derived Xenograft (PDX) Models Market Key Performance Indicators |
8.1 Average time taken for drug development using PDX models |
8.2 Number of collaborations between research institutions and pharmaceutical companies for PDX model research |
8.3 Percentage increase in funding allocated to PDX model research in Australia |
9 Australia Patient Derived Xenograft (PDX) Models Market - Opportunity Assessment |
9.1 Australia Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Type, 2022 & 2032F |
9.2 Australia Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Tumor Type, 2022 & 2032F |
9.3 Australia Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Application, 2022 & 2032F |
9.4 Australia Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Technique, 2022 & 2032F |
9.5 Australia Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By End User, 2022 & 2032F |
10 Australia Patient Derived Xenograft (PDX) Models Market - Competitive Landscape |
10.1 Australia Patient Derived Xenograft (PDX) Models Market Revenue Share, By Companies, 2025 |
10.2 Australia Patient Derived Xenograft (PDX) Models Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here